Table of Contents
Journal of Cancer Research
Volume 2013 (2013), Article ID 480608, 9 pages
http://dx.doi.org/10.1155/2013/480608
Review Article

Bleomycin-Induced Lung Injury

Serviço de Oncologia Clínica, Instituto Nacional de Câncer (INCA), Praça da Cruz Vermelha 23, 20230-130 Rio de Janeiro, RJ, Brazil

Received 8 April 2013; Accepted 16 September 2013

Academic Editor: Rainald Knecht

Copyright © 2013 Tomás Reinert et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Sleijfer, “Bleomycin-induced pneumonitis,” Chest, vol. 120, no. 2, pp. 617–624, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Spence, T. Krings, K. G. TerBrugge, L. B. Da Costa, and R. Agid, “Percutaneous sclerotherapy for facial venous malformations: Subjective clinical and objective MR imaging follow-up results,” American Journal of Neuroradiology, vol. 31, no. 5, pp. 955–960, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. R. M. Burger, J. Peisach, and S. B. Horwitz, “Activated bleomycin. A transient complex of drug, iron, and oxygen that degrades DNA,” The Journal of Biological Chemistry, vol. 256, no. 22, pp. 11636–11644, 1981. View at Google Scholar · View at Scopus
  4. J. Chen and J. Stubbe, “Bleomycins: towards better therapeutics,” Nature Reviews Cancer, vol. 5, no. 2, pp. 102–112, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Chu and V. T. DeVita Jr., Cancer Chemotherapy Drug Manual, Jones and Bartlett, Boston, Mass, USA, 2011.
  6. A. A. Ferrando, A. M. Pendás, E. Llano, G. Velasco, R. Lidereau, and C. López-Otín, “Gene characterization, promoter analysis, and chromosomal localization of human bleomycin hydrolase,” The Journal of Biological Chemistry, vol. 272, no. 52, pp. 33298–33304, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. P. J. Santrach, F. B. Askin, R. J. Wells, R. G. Azizkhan, and D. F. Merten, “Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma,” Cancer, vol. 64, no. 4, pp. 806–811, 1989. View at Google Scholar · View at Scopus
  8. K. Jules-Elysee and D. A. White, “Bleomycin-induced pulmonary toxicity,” Clinics in Chest Medicine, vol. 11, no. 1, pp. 1–20, 1990. View at Google Scholar · View at Scopus
  9. A. B. Simpson, J. Paul, J. Graham, and S. B. Kaye, “Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours,” British Journal of Cancer, vol. 78, no. 8, pp. 1061–1066, 1998. View at Google Scholar · View at Scopus
  10. G. Kessell, S. Panchatsharam, E. Kothmann et al., “General anaesthesia for intralesional bleomycin therapy of vascular malformations: initial 3 yr experience,” British Journal of Anaesthesia, vol. 102, no. 3, pp. 431–432, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. I. Uzel, M. Ozguroglu, B. Uzel et al., “Delayed onset bleomycin-induced pneumonitis,” Urology, vol. 66, no. 1, pp. 195e.23–195e.25, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Bollée, C. Sarfati, G. Thiéry et al., “Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients,” Chest, vol. 132, no. 4, pp. 1305–1310, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. P. W. Van Barneveld, D. T. Sleijfer, T. W. van der Mark et al., “Natural course of bleomycin-induced pneumonitis. A follow-up study,” American Review of Respiratory Disease, vol. 135, no. 1, pp. 48–51, 1987. View at Google Scholar · View at Scopus
  14. E. H. Herman, B. B. Hasinoff, J. Zhang et al., “Morphologic and morphometric evaluation of the effect of ICRF-187 on bleomycin-induced pulmonary toxicity,” Toxicology, vol. 98, no. 1–3, pp. 163–175, 1995. View at Publisher · View at Google Scholar · View at Scopus
  15. D. B. Chandler, “Possible mechanisms of bleomycin-induced fibrosis,” Clinics in Chest Medicine, vol. 11, no. 1, pp. 21–30, 1990. View at Google Scholar · View at Scopus
  16. M. Yoshida, J. Sakuma, S. Hayashi et al., “A histologically distinctive interstitial pneumonia induced by overexpression of the interleukin 6, transforming growth factor β1, or platelet-derived growth factor b gene,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 21, pp. 9570–9574, 1995. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Kuwano, N. Hagimoto, M. Kawasaki et al., “Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis,” The Journal of Clinical Investigation, vol. 104, no. 1, pp. 13–19, 1999. View at Google Scholar · View at Scopus
  18. J. A. D. Cooper Jr., D. A. White, and R. A. Matthay, “Drug-induced pulmonary disease. Part 1: cytotoxic drugs,” American Review of Respiratory Disease, vol. 133, no. 2, pp. 321–340, 1986. View at Google Scholar · View at Scopus
  19. S. L. King, A. C. Lichtler, D. W. Rowe et al., “Bleomycin stimulates pro-α1(I) collagen promoter through transforming growth factor β response element by intracellular and extracellular signaling,” The Journal of Biological Chemistry, vol. 269, no. 18, pp. 13156–13161, 1994. View at Google Scholar · View at Scopus
  20. E. M. Denholm and S. H. Phan, “Bleomycin binding sites on alveolar macrophages,” Journal of Leukocyte Biology, vol. 48, no. 6, pp. 519–523, 1990. View at Google Scholar · View at Scopus
  21. C. Isabela, S. Silva, and N. L. Müller, “Drug-induced lung diseases: most common reaction patterns and corresponding CT manifestations,” Seminars in Ultrasound, CT and MRI, vol. 27, no. 2, pp. 111–116, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. D. A. White, M. G. Kris, and D. E. Stover, “Bronchoalveolar lavage cell populations in bleomycin lung toxicity,” Thorax, vol. 42, no. 7, pp. 551–552, 1987. View at Google Scholar · View at Scopus
  23. M. De Lena, A. Guzzon, S. Monfardini, and G. Bonadonna, “Clinical, radiologic, and histopathologic studies on pulmonary toxicity induced by treatment with bleomycin (NSC-125066),” Cancer Chemotherapy Reports, vol. 56, no. 3, pp. 343–356, 1972. View at Google Scholar · View at Scopus
  24. T. Sikdar, D. Macvicar, and J. E. Husband, “Pneumomediastinum complicating bleomycin related lung damage,” British Journal of Radiology, vol. 71, pp. 1202–1204, 1998. View at Google Scholar · View at Scopus
  25. M. B. Cohen, J. H. M. Austin, A. Smith-Vaniz, J. Lutzky, and M. M. Grimes, “Nodular bleomycin toxicity,” American Journal of Clinical Pathology, vol. 92, no. 1, pp. 101–104, 1989. View at Google Scholar · View at Scopus
  26. T. Buchler, J. Bomanji, and S. M. Lee, “FDG-PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin's disease—a useful tool for monitoring pulmonary toxicity and disease activity,” Haematologica, vol. 92, no. 11, pp. 120–121, 2007. View at Google Scholar · View at Scopus
  27. R. de Wit, G. Stoter, S. B. Kaye et al., “Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group,” Journal of Clinical Oncology, vol. 15, no. 5, pp. 1837–1843, 1997. View at Google Scholar · View at Scopus
  28. J. Wolkowicz, J. Sturgeon, M. Rawji, and C. K. Chan, “Bleomycin-induced pulmonary function abnormalities,” Chest, vol. 101, no. 1, pp. 97–101, 1992. View at Google Scholar · View at Scopus
  29. J. M. O'Sullivan, R. A. Huddart, A. R. Norman, J. Nicholls, D. P. Dearnaley, and A. Horwich, “Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours,” Annals of Oncology, vol. 14, no. 1, pp. 91–96, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. H. S. Haugnes, N. Aass, S. D. Fosså et al., “Pulmonary function in long-term survivors of testicular cancer,” Journal of Clinical Oncology, vol. 27, no. 17, pp. 2779–2786, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Kawai, S. Hinotsu, M. Tomobe, and H. Akaza, “Serum creatinine level during chemotherapy for testicular cancer as a possible predictor of bleomycin-inducedpulmonary toxicity,” Japanese Journal of Clinical Oncology, vol. 28, no. 9, pp. 546–550, 1998. View at Google Scholar · View at Scopus
  32. S. M. Donat and D. A. Levy, “Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary?” Journal of Urology, vol. 160, no. 4, pp. 1347–1352, 1998. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Danson, F. Blackhall, P. Hulse, and M. Ranson, “Interstitial lung disease in lung cancer: Separating disease progression from treatment effects,” Drug Safety, vol. 28, no. 2, pp. 103–113, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. S. B. Saxman, C. R. Nichols, and L. H. Einhorn, “Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor,” Chest, vol. 111, no. 3, pp. 657–660, 1997. View at Google Scholar · View at Scopus
  35. P. J. Loehrer, D. Johnson, P. Elson et al., “Importance of bleomycin in combination with chemotherapy for good-prognosis testicular non-seminoma,” Journal of Clinical Oncology, vol. 15, pp. 1837–1843, 1997. View at Google Scholar
  36. L. H. Einhorn, S. D. Williams, P. J. Loehrer et al., “Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group Protocol,” Journal of Clinical Oncology, vol. 7, no. 3, pp. 387–391, 1989. View at Google Scholar · View at Scopus
  37. C. R. Nichols, P. J. Catalano, E. D. Crawford, N. J. Vogelzang, L. H. Einhorn, and P. J. Loehrer, “Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and cancer and leukemia group B study,” Journal of Clinical Oncology, vol. 16, no. 4, pp. 1287–1293, 1998. View at Google Scholar · View at Scopus
  38. G. P. Canellos, J. R. Anderson, K. J. Propert et al., “Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD,” The New England Journal of Medicine, vol. 327, no. 21, pp. 1478–1484, 1992. View at Google Scholar · View at Scopus
  39. G. P. Canellos, J. Gollub, D. Neuberg, P. Mauch, and L. N. Shulman, “Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up,” Annals of Oncology, vol. 14, no. 2, pp. 268–272, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. R. M. Meyer, M. K. Gospodarowicz, J. M. Connors et al., “ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma,” The New England Journal of Medicine, vol. 366, no. 5, pp. 399–408, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. N. Hashimoto, S. H. Phan, K. Imaizumi et al., “Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis,” American Journal of Respiratory Cell and Molecular Biology, vol. 43, no. 2, pp. 161–172, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. P. F. Piguet, C. Vesin, G. E. Grau, and R. C. Thompson, “Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica,” Cytokine, vol. 5, no. 1, pp. 57–61, 1993. View at Publisher · View at Google Scholar · View at Scopus
  43. L. Nici and P. Calabresi, “Amifostine modulation of bleomycin-induced lung injury in rodents,” Seminars in Oncology, vol. 26, no. 2, pp. 28–33, 1999. View at Google Scholar · View at Scopus
  44. P. F. Piguet, M. A. Collart, G. E. Grau, Y. Kapanci, and P. Vassalli, “Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis,” The Journal of Experimental Medicine, vol. 170, no. 3, pp. 655–663, 1989. View at Google Scholar · View at Scopus
  45. S. N. Giri, D. M. Hyde, and M. A. Hollinger, “Effect of antibody to transforming growth factor β on bleomycin induced accumulation of lung collagen in mice,” Thorax, vol. 48, no. 10, pp. 959–966, 1993. View at Google Scholar · View at Scopus
  46. R. T. Dackor, J. Cheng, J. W. Voltz et al., “Prostaglandin E2 protects murine lungs from bleomycin-induced pulmonary fibrosis and lung dysfunction,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 301, no. 5, pp. L645–L655, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. E. A. Bellamy, J. E. Husband, R. M. Blaquiere, and M. R. Law, “Bleomycin-related lung damage: CT evidence,” Radiology, vol. 156, no. 1, pp. 155–158, 1985. View at Google Scholar · View at Scopus
  48. D. A. White and D. E. Stover, “Severe bleomycin-induced pneumonitis. Clinical features and response to corticosteroids,” Chest, vol. 86, no. 5, pp. 723–728, 1984. View at Google Scholar · View at Scopus
  49. A. J. Fyfe and P. McKay, “Toxicities associated with bleomycin,” Journal of the Royal College of Physicians of Edinburgh, vol. 40, no. 3, pp. 213–215, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. B. Tulek, E. Kiyan, H. Toy, A. Kiyici, C. Narin, and M. Suerdem, “Anti-inflammatory and anti-fibrotic effects of sirolimus on bleomycin-induced pulmonary fibrosis in rats,” Clinical and Investigative Medicine, vol. 34, no. 6, p. E341, 2011. View at Google Scholar · View at Scopus
  51. P. Wang, Q. Tian, Z.-X. Liang et al., “Gefitinib attenuates murine pulmonary fibrosis induced by bleomycin,” Chinese Medical Journal, vol. 123, no. 16, pp. 2259–2264, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. C. Shimbori, N. Shiota, and H. Okunishi, “Effects of montelukast, a cysteinyl-leukotriene type 1 receptor antagonist, on the pathogenesis of bleomycin-induced pulmonary fibrosis in mice,” European Journal of Pharmacology, vol. 650, no. 1, pp. 424–430, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. C. K. Rhee, S. H. Lee, H. K. Yoon et al., “Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice,” Respiration, vol. 82, no. 3, pp. 273–287, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. G. J. Rey-Parra, A. Vadivel, L. Coltan et al., “Angiotensin converting enzyme 2 abrogates bleomycin-induced lung injury,” Journal of Molecular Medicine, vol. 90, no. 6, pp. 637–647, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. J. W. Kim, C. K. Rhee, T. J. Kim et al., “Effect of pravastatin on bleomycin-induced acute lung injury and pulmonary fibrosis,” Clinical and Experimental Pharmacology and Physiology, vol. 37, no. 11, pp. 1055–1063, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. P. D. Vermeer, L. A. Einwalter, T. O. Moninger et al., “Segregation of receptor and ligand regulates activation of epithelial growth factor receptor,” Nature, vol. 422, no. 6929, pp. 322–326, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. J. A. Faress, D. E. Nethery, E. F. O. Kern et al., “Bleomycin-induced pulmonary fibrosis is attenuated by a monoclonal antibody targeting HER2,” Journal of Applied Physiology, vol. 103, no. 6, pp. 2077–2083, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. S. Murphy, R. Lim, H. Dickinson et al., “Human amnion epithelial cells prevent bleomycin-induced lung injury and preserve lung function,” Cell Transplantation, vol. 20, no. 6, pp. 909–923, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. F. Carnevale-Schianca, S. Gallo, D. Rota-Scalabrini et al., “Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with hodgkin's lymphoma: hope for severe chemotherapy-induced toxicity?” Journal of Clinical Oncology, vol. 29, no. 24, pp. e691–e693, 2011. View at Publisher · View at Google Scholar · View at Scopus